Vapotherm provides high velocity nasal insufflation (HVNI) with simultaneous oxygen delivery to augment breathing of spontaneously breathing patients suffering from respiratory distress and/or hypoxemia in the hospital setting. It is not intended to provide total ventilatory requirements of the patient and not for use during field transport.
The information provided in this section is for educational purposes only. This information is not intended to support the safety or effectiveness of Vapotherm products, or diagnose, treat, cure, or prevent any disease. It is not a substitute for consultation with your healthcare provider and should not be construed as medical advice.
COVID Delta Expert Panel Discussion
Dr. Kirk Hinkley, MD FACEP, facilitates a panel discussion with Emergency Medicine and Critical Care Physicians about their experience with the current COVID Delta Variant surge in some of the most impacted areas of the United States. The Panel covers how this surge is different from previous ones and the effect it has had on
Children’s Hospital Respiratory Department Operations
Garry Kauffman, RRT FAARC MPA FACHE, former AARC President, interviews Dave Crotwell, Respiratory Director for a tertiary Children’s Hospital in the Northwest to understand operational differences in a Children’s Hospital to Adult Hospital’s operations, specifically, as it relates to reimbursement, billing and productivity. Although Children’s Hospitals largely have avoided capitated payment models that other Short Term Acute Care Hospitals have worked under since CMS
Respiratory Department Directors Discuss Productivity
John Walsh, Vapotherm VP of Clinical, sits down with Ed Garcia and Jonathan Butler, two current and longtime Respiratory Department Directors, to discuss Respiratory Department Productivity. Ed and Jonathan provide overviews of their current productivity systems and how they work with their leadership, finance and IT Teams to recognize the work that their department does (billable and non-billable; clinical, clinical support
Safe Patient Care with Vapotherm High Velocity Therapy
Whether on the general care floor, in the emergency room, or the ICU, Vapotherm devices are designed with patient safety in mind. There are inherent risks in using any medical device on sick patients. Here are the ways in which we strive to give you confidence that you’re providing your respiratory distress patient with safe
AARC Safe and Effective Staffing Guide Recognizes High Velocity Therapy as NIV
The AARC released their Safe and Effective Staffing Guide (previous known as the AARC Uniform Reporting Manual (URM)), the association’s official productivity guide with time standards for most Respiratory Care Department procedures. The time standards are based on 2020 survey results from hundreds of US Respiratory Care Department Directors and Managers. In the new guide, high
New Analysis Shows that Preterm Babies Can Be Effectively Stabilized in Delivery Room Using Vapotherm® as Primary Respiratory Support
In February 2021, Siva and Reynolds published the results of a retrospective, single center, observational cohort study in Acta Paediatrica titled “Stabilisation of the preterm infant in the delivery room using nasal high flow: A 5—year retrospective analysis.” The analysis examined the clinical outcomes of premature neonates stabilized in the delivery room to determine the
New Study Adds Evidence for Use of Vapotherm® High Velocity Therapy as First-Line Support on Severely Hypercapnic COPD Patients
Vapotherm high velocity therapy is an attractive alternative to traditional noninvasive positive pressure ventilation (NiPPV) for respiratory distress. This approach — which is a form of Mask-Free NIV® — redefines the notion that ventilatory support requires a mask-and-pressure-based mechanism of action.
Keeping This Complex COVID-19 Patient Off the Vent —A Case Story of Inhaled Epoprostenol, High Velocity Therapy, and Healthcare Team Perseverance
Although individual results may vary, Vapotherm believes this case story is an example of the clinical benefit Vapotherm’s high velocity therapy can have in an ICU setting. About six months into the COVID-19 pandemic, 61-year-old Ethan* was admitted to the ICU with complications from COVID-19 and comorbidities including stage III chronic kidney disease.
Velocity – Ep 9 – Physicians discuss research on Mask-Free NIV for COPD patients
In this episode, Dr. Kirk Hinkley interviews esteemed researcher and pulmonologist Dr. Charles Atwood about the latest research concerning use of high velocity therapy for COPD patients. They discuss an article by Doshi and colleagues published in March of 2020 in Heart & Lung. Dr. Atwood breaks down the research and offers his insight as to the clinical practice implications of the results.
BreatheTV Episode 25 – Importance of Early Mobilization | A Webinar with NAN Nathenson, RRT
Jeff Maglin: It’s now my pleasure to introduce our speaker Nan Nathenson. Nan is a respiratory therapist and educator. She has worked in nearly every level care including critical care and rehabilitation settings. In her experience, she has narrowed the gaps between levels of care.